<DOC>
	<DOC>NCT02921802</DOC>
	<brief_summary>To understand the safety and efficacy of RevlimidÂ® 5 mg Capsules (hereinafter referred to as Revlimid) in all patients who are treated with it under the actual condition of use pursuant to the conditions of approval. 1. Planned registration period This period started on the date of initial marketing of Revlimid and will end at the time when the planned number of patients to be enrolled is reached. 2. Planned surveillance period This period started on the date of initial marketing of Revlimid and will end on the day when the approval condition related to all-case surveillance is terminated.</brief_summary>
	<brief_title>A Study of Special Use Results Surveillance of Revlimid 5mg Capsules</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Among relapsed or refractory multiple myeloma and Myelodysplastic syndrome (MDS) with a deletion 5q cytogenetic abnormality patients, all patients who received Revlimid will be targeted in this surveillance.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Teratogenicity</keyword>
	<keyword>Thrombocytopenia and haemorrhage</keyword>
	<keyword>Neutropenia and infection</keyword>
	<keyword>Venous thromboembolism</keyword>
	<keyword>Allergic reactions</keyword>
	<keyword>Diarrhoea or constipation</keyword>
	<keyword>Peripheral neuropathy</keyword>
	<keyword>Cardiac failure</keyword>
	<keyword>Arrhythmia</keyword>
	<keyword>Renal failure</keyword>
	<keyword>Myocardial infarction</keyword>
	<keyword>Interstitial lung disease</keyword>
	<keyword>Tumour lysis syndrome</keyword>
	<keyword>Transformation from myelodysplastic syndrome to acute myeloid leukemia</keyword>
</DOC>